News Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
0.2827 ^USD	-41.70%		-40.93%	-8.51%

Mar. 28	Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024
Mar. 28	Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Apr. 11	AQ
Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024	Mar. 28
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update	Mar. 28	AQ
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024	Mar. 21	AQ
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting	Feb. 22	AQ
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	AQ
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31	CI
Daré Bioscience, Inc. Announces Executive Changes	Jan. 26	CI
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer	Jan. 26	CI
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	Jan. 26	MT
Daré Bioscience Announces Executive Team and Board of Directors Changes	Jan. 26	AQ
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development	Jan. 17	AQ
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases	Jan. 04	AQ
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure	Dec. 26	AQ
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study	Dec. 20	AQ
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	Dec. 20	CI
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study	Dec. 13	AQ
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	Dec. 07	MT
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause	Dec. 07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Summary

Filters